ClinicalTrials.gg
Active, not recruitingNCT06527365Updated Nov 6, 2025

Safety and Efficacy of VDPHL01 in Males and Females With AGA

A Phase 2 interventional study of VDPHL01 in Androgenetic Alopecia, AGA and Male Pattern Baldness, sponsored by Veradermics, Inc.. Active, not recruiting at 4 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-11-06.

Sponsored by Veradermics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
70
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 216 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Planned enrollment
63rd of 203
70 · median 40
Started
2024
with 19 others
Phase 2
47 of 216
6 open now
Primary completion
2026-08
later than 19 of 62 live
Registered
177th of 216
by date

Among the 216 studies in Alopecia with a site in United States, this one is the 63rd largest by planned enrollment of the 203 interventional ones that give a count, is one of 20 that started in 2024, is one of 47 in phase 2, reaches primary completion later than 19 of the 62 other live ones, and was the 177th registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 129 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 216 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 216 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA).

AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness.

This multiple center, open-label, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). Male subjects that meet the study eligibility criteria will be administered VDPHL01 once daily for 12 months. Female subjects that meet the study eligibility criteria will be administered VDPHL01 either once or twice daily for 12 months.

03

Conditions studied

  • Androgenetic Alopecia
  • AGA
  • Male Pattern Baldness

Browse trials for

Keywords

  • Hair Loss
  • Male Hair Loss
  • Female Hair Loss
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is male or non-pregnant female aged 18-65 years old;
  • Subject has a clinical diagnosis of mild to moderate AGA;
  • Subject is in good general health and has normal renal and hepatic function;
  • Subject is willing to maintain at least 1/4 inch length hair during the study with the same hairstyle, hair length, and hair color throughout the study; maintain consistent use of general hair care products and regimen through the entire study;
  • Subject is willing and able to administer the test article as directed read, understand, and complete required questionnaires in English;
  • Subject agrees to have a micro dot tattoo placed on their scalp;
  • Subject agrees to have this area photographed at study visits as indicated in the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has uncontrolled blood pressure;
  • Subject has symptoms or history of certain heart or thyroid conditions;
  • Subject has a history of cardiac and/or thyroid diseases;
  • Subject has received an organ transplant;
  • Subject has a history of prescription drug abuse or illicit drug use within 6 months of screening; history of alcohol abuse within 6 months prior to screening;
  • Subject has a current or recent history of dietary or weight changes;
  • Subject has been diagnosed with COVID-19 within 16 weeks of baseline;
  • Subject has used any topical scalp treatments for hair growth within 4 weeks prior to screening;
  • Subject has had any scalp procedures, including surgical, laser, light or energy treatments, micro-needling, etc. within 6 months prior to screening;
  • Subject has had previous radiation of the scalp;
  • Subject has used systemic cimetidine, ketoconazole, diazoxide, or (including intramuscular, intraarticular, and intralesional injections) within 12 weeks prior to screening;
  • Subject has used systemic beta blockers within 12 weeks prior to screening;
  • Subject is currently enrolled in an drug, biologic, or device study or has used an investigational treatment within 30 days prior to screening;
  • Subject has used any other therapy with any medication either topical or oral that might, in the investigator's opinion, interfere with the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
70 participants (estimated)

Study arms

  • Experimental
    VDPHL01 Tablet

    Drug: VDPHL01

Interventions

  • VDPHL01 Extended Release (ER) Tablet

06

What researchers measure

Primary outcomes

  1. Changes in non-vellus Total Area Hair Count (TAHC)

    Change from baseline in non-vellus TAHC using digital image analysis at Month 12.

    Time frame: Month 12

  2. Subjects Evaluation of Treatment Benefit

    Subjects will rate their treatment benefit by responding to a hair assessment scale. The proportion of subjects by each response category will be reported at Month 12.

    Time frame: Month 12

07

Study locations

4 sites
  • 01
    San Diego, California 92123, United States
  • 04
    New Albany, Indiana 47150, United States
  • 03
    Hackensack, New Jersey 07601, United States
  • 02
    South Jordan, Utah 84095, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Aug 2026, 25 months after the start.

Of 25 industry-sponsored phase 2 interventional studies under Alopecia, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 25 months is above that.

Counting every sponsor, half of 42 studies reached it within 13 months; a quarter within 9 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2024
First posted
Jul 30, 2024
StartActual
Jul 8, 2024
Primary completionEst.
Aug 2026
CompletionEst.
Aug 2026
Last update
Nov 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06527365
Lead sponsor
Veradermics, Inc.
Responsible party
Sponsor
First posted
Jul 30, 2024
Start date
Jul 8, 2024
Primary completion
Aug 2026 (estimated)
Completion
Aug 2026 (estimated)
Last update
Nov 6, 2025

Study contacts

Reid Waldman, M.D.
study chair · Veradermics, Inc.
Timothy Durso, M.D.
study director · Veradermics, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VDPHL01

Start the discussion